Flexible Stenting Solutions (FSS) has treated the first two patients in a clinical trial using the FlexStent Femoro popliteal self-expanding stent.

The prospective single-arm evaluation of safety and efficacy of the FlexStent clinical trial enrolled up to 227 patients in order to evaluate the safety and efficacy of the FlexStent for the treatment of patients with peripheral arterial disease.

FSS also focused on physician requests for a flexible, durable, conformable and easy-to-deliver stent.

The FlexStent system has already received CE Mark approval for peripheral vascular use and US 510(k) clearance for palliative treatment of biliary strictures produced by malignant neoplasms.